Ovitrelle 250mcg Injection

Ovitrelle® 250 mcg Injection (Choriogonadotropin Alfa 250 mcg)

Choriogonadotropin Alfa 250 mcg Injection (Brand: Ovitrelle®, known as Ovidrel® in the United States) is a prescription recombinant human chorionic gonadotropin (r-hCG) injection used to trigger final follicular maturation and ovulation in women undergoing fertility treatment. It is widely prescribed by fertility specialists as part of assisted reproductive technology (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), controlled ovarian stimulation (COS), and ovulation induction.

Unlike urinary-derived hCG products, Ovitrelle® 250 mcg Injection contains recombinant Choriogonadotropin Alfa, manufactured using recombinant DNA technology to provide a highly purified and consistent formulation. It mimics the body’s natural luteinizing hormone (LH) surge, helping mature ovarian follicles release an egg at the optimal time for natural conception, intrauterine insemination (IUI), or egg retrieval during IVF treatment.

Ovitrelle is commonly prescribed for women with anovulation, ovulatory dysfunction, polycystic ovary syndrome (PCOS), unexplained infertility, and those undergoing fertility treatment with gonadotropins. The injection is administered only after adequate follicular development has been confirmed by ultrasound and hormone monitoring, ensuring optimal timing for ovulation and improving the chances of successful fertilization.

As a globally recognized fertility medicine, Ovitrelle® (Ovidrel® in the U.S.) has become an integral part of modern reproductive medicine. Clinical guidelines support its use in appropriately selected patients undergoing assisted reproduction under the supervision of reproductive endocrinologists and fertility specialists.

Whether you are searching for Ovitrelle 250 mcg Injection, Choriogonadotropin Alfa Injection, Ovidrel Injection, recombinant hCG injection, IVF trigger shot, ovulation trigger injection, or fertility hormone injection, this medicine is trusted by fertility clinics worldwide for its predictable pharmacological profile and consistent clinical performance.

Purchase Ovitrelle® 250 mcg Injection from a trusted pharmaceutical supplier offering authentic fertility medications, secure ordering, competitive pricing, and worldwide shipping where permitted by local regulations. We supply genuine reproductive medicines to hospitals, fertility clinics, licensed pharmacies, healthcare professionals, and eligible patients.

Frequently Asked Questions (FAQs)

What is Ovitrelle® 250 mcg Injection used for?

Ovitrelle® 250 mcg Injection is used to trigger final egg maturation and ovulation in women undergoing fertility treatment, including IVF, ICSI, IUI, controlled ovarian stimulation, and ovulation induction.

Is Ovitrelle the same as Ovidrel?

Yes. Ovitrelle® and Ovidrel® contain the same active ingredient, Choriogonadotropin Alfa 250 mcg. Ovitrelle is marketed in many countries outside the United States, while Ovidrel® is the U.S. brand name.

How does Ovitrelle work?

Ovitrelle mimics the body’s natural luteinizing hormone (LH) surge, triggering the final maturation and release of a mature egg from the ovarian follicle at the appropriate time during fertility treatment.

When is Ovitrelle given during IVF?

The injection is typically administered after ultrasound confirms adequate follicular development. Egg retrieval is usually scheduled approximately 34–36 hours after the trigger injection, following the fertility specialist’s treatment protocol.

Is Ovitrelle a recombinant hCG injection?

Yes. Ovitrelle contains recombinant human chorionic gonadotropin (r-hCG), produced using recombinant DNA technology rather than being extracted from human urine.

Who should use Ovitrelle?

Ovitrelle is prescribed for women undergoing assisted reproductive technology (ART), ovulation induction, or fertility treatment. It should only be used under the guidance of a qualified fertility specialist.

What are the possible side effects of Ovitrelle?

Common side effects include injection-site reactions, headache, nausea, abdominal discomfort, pelvic pain, and fatigue. Rare but serious complications, such as ovarian hyperstimulation syndrome (OHSS), require immediate medical attention.